Publication: Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19.
Loading...
Identifiers
Date
2022-01-21
Authors
Lavilla Olleros, Cristina
Ausín García, Cristina
Bendala Estrada, Alejandro David
Muñoz, Ana
Wikman Jogersen, Philip Erick
Fernández Cruz, Ana
Giner Galvañ, Vicente
Vargas, Juan Antonio
Seguí Ripoll, José Miguel
Rubio-Rivas, Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses.
Description
MeSH Terms
Adrenal Cortex Hormones
Adult
Age Factors
Aged
Aged, 80 and over
COVID-19
Drug Administration Schedule
Female
Hospital Mortality
Humans
Male
Middle Aged
Prednisone
Registries
SARS-CoV-2
Sepsis
Spain
Survival Analysis
Treatment Outcome
COVID-19 Drug Treatment
Adult
Age Factors
Aged
Aged, 80 and over
COVID-19
Drug Administration Schedule
Female
Hospital Mortality
Humans
Male
Middle Aged
Prednisone
Registries
SARS-CoV-2
Sepsis
Spain
Survival Analysis
Treatment Outcome
COVID-19 Drug Treatment